Integra Lifesciences Holdings Stock News

Integra LifeSciences Holdings Corp (NASDAQ: IART ) expects Q4 FY21 sales of $404 million - $406 million , representing an increase of approximately 4% Y/Y on a reported basis and 8% on an organic basis. Interim Q4 sales beat the consensus of $403.9 million. In its

Integra LifeSciences Holdings Corp (NASDAQ: IART) expects Q4 FY21 sales of $404 million - $406 million, representing an increase of approximately 4% Y/Y on a reported basis and 8% on an organic basi

Integra LifeSciences Holdings (IART) releases its preliminary revenue estimate for fourth quarter that lands slightly above the market expectation. The medical technology on Tuesday

Integra LifeSciences (IART) has reported preliminary financial results, expecting Q421 revenue in the range of $404M to $406M (up around 4% Y/Y on a reported basis and +8% on an

Fourth quarter 2021 revenue is expected to be in a range of $404 million to $406 million, representing an increase of approximately 4% on a reported basis and an increase of approximately 8% on an organic basis compared to the prior year. Full-year 2021 revenue is expected to be in a range of $1,541 million to $1,543 million, representing an increase of approximately 12% on a reported basis and an increase of approximately 14% on an organic basis compared to the prior year. The company is planning a $125 million share repurchase as a part of a previous approval by the Board of Directors, with an authorization of up to $225 million. PRINCETON, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART ), a leading global medical technology company, announced today certain unaudited preliminary fourth quarter and full-year 2021 revenue results. Preliminary Fourth Quarter and Full-Year 2021 Revenue Results Fourth quarter 2021 revenue is expected to be in a range of $404 million to $406 million, representing an increase of approximately 4% on a reported basis and an increase of approximately 8% on an organic basis compared to the prior year.

Texas Permanent School Fund boosted its position in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 1.7% during the 3rd quarter, Holdings Channel reports. The fund owned 53,807 shares of the life sciences companys stock after buying an additional 880 shares during the period. Texas Permanent School Funds holdings in Integra LifeSciences were worth $3,685,000 as of [] The post Texas Permanent School Fund Purchases 880 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) appeared first on ETF Daily News .

Los Angeles, United State: The report is a compilation of comprehensive research studies on various aspects of the global Cerebrospinal Fluid Management Devices Market. With accurate data and highly authentic information, it makes a brilliant attempt to provide a real,

Integra's (IART) ongoing sales recovery across geographies and product lines looks encouraging.

Integra LifeSciences (NASDAQ:IART) was upgraded by equities research analysts at JPMorgan Chase & Co. from an underweight rating to a neutral rating in a report released on Friday, Analyst Ratings Network reports. The brokerage currently has a $75.00 target price on the life sciences companys stock. JPMorgan Chase & Co.s price target points to a []

AMG National Trust Bank raised its position in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 1.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,240 shares of the life sciences companys stock after purchasing an additional 200 shares during the period. AMG National Trust Banks []

Medical Gauze And Tapes market report always keeps a goal to provide thorough understanding of the entire market. In order to secure the funds of the industries, it aims at providing some independent facts. It further goes on delivering

Karp Capital Management Corp bought a new stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 5,025 shares of the life sciences companys stock, valued at approximately $344,000. Several other hedge funds also recently made changes to []

Related Stocks: FHB , LITE , HRI , SWX , GT , XEC , ON , IART , ACHC , CHNG , BNL , WHD , STL , XPO , FL , ALK , SHOO , HI ,

According to Market Study Report, Chitosan Based Hydrogel Market provides a comprehensive analysis of the Chitosan Based Hydrogel Market segments, including their dynamics, size, growth, regulatory requirements, competitive landscape, and emerging opportunities of global industry. An exclusive data offered in

New Jersey, United Kingdom, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Facts and Factors have published a new research report titled "Veterinary Surgical Instruments Market By Instrument Type (Handheld Devices, Electrosurgery Instrument, Suture, Staplers, & Accessories, & Others), By Animal Type (Large Animal & Small Animal), By Application (Soft Tissue Surgery, Cardiovascular Surgery, Ophthalmic Surgery, Dental Surgery, Orthopedic Surgery, & Others), And By Regions - Global & Regional Industry Perspective, Comprehensive Analysis, and Forecast 2021 2026" in its research database "According to the latest research study, the demand of global Veterinary Surgical Instruments Market size & share expected to reach to USD 1,023.5 Million by 2026 from USD 783.9 Million in 2020, at a compound annual growth rate (CAGR) of 6.8% during the forecast period 2021 to 2026" How Big is Veterinary Surgical Instruments Market? Report Overview & Coverage: Veterinary surgical instruments are the tools that are often used by veterinaries for performing surgeries which can be categorized into three broad categories Orthopedics (Bones, joints, and muscles), soft tissue surgery (skin, body cavities, and GI/respiratory tracts), and neurosurgery.